Open Label Clinical Study to Assess the Clinical Safety of a New Compression Device in Subjects With Peripheral Arterial Vascular Disease

NCT ID: NCT00854516

Last Updated: 2024-10-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2010-01-31

Brief Summary

To assess the safety of a new compression device applied to patients with an ankle brachial pressure index (ABPI) 0,5 - 0,8 who are treated for two weeks in daily routine practice. Several perfusion assessments will investigate safety under reduced compression therapy.

Detailed Description

Venous leg ulcers represent a very common clinical problem with increasing prevalence in an aging population. It is believed that venous insufficiency is the underlying condition responsible for 54-81% of leg ulcers. About 8% of leg ulcers are related to arterial insufficiency and about 14% have a mixed aetiology. Compression therapy is considered the most effective treatment for these ulcers. The overall cost of chronic venous leg ulcer is high because long term ongoing care is required. Also the quality of life of these patients is jeopardized due to long lasting ulcer treatments and inconvenient compression therapies.

Several compression products are available on the market and there is a large body of literature describing the clinical benefit of different compression systems.

A new treatment approach with the new device is to have an effective working pressure combined with a low resting pressure. A high working pressure achieved by a rigid sleeve around a patient's leg is essential to support the muscle pump, necessary for sufficient blood reflux. However the resting pressure could be low without relevant reduction of compression efficacy but with an increase in safety for patients with a mild to moderate peripheral arterial occlusive disease (PAOD). A high resting pressure is believed to be a main reason for reduced arterial skin perfusion which can result in pressure related skin damage. Accordingly most compression systems are not indicated for patients with an ABPI lower than 0.8. About 25% of patients with chronic venous insufficiency suffer from PAOD and hence are very difficult to treat with compression. With the new device, these patients could be sufficiently treated, because a low resting pressure is believed to have low influence on skin perfusion.

Conditions

Peripheral Arterial Vascular Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

A new treatment approach is to have an effective working pressure combined with a low resting pressure.

Procedure Schedule: The total duration for study participation will be 14 days (8 visits).

Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Males or females, age 18 years or older.

2. Subjects suffering from peripheral arterial occlusive disease (PAOD) with an ABPI (ankle brachial pressure index) of the treated leg between 0.5 - 0.8 as measured within up to 4 weeks prior to enrollment. About 5 subjects of the study population should have an ABPI of 0.5.

3. Subjects who are co-operative, willing to give written informed consent prior to study entry and willing to comply with the study protocol.

4. Subjects who can walk (with or without a walking aid).

-

Exclusion Criteria

1. Subjects with an ABPI < 0.5 or > 0.8 as measured within up to 4 weeks prior to enrollment.

2. Subjects whose general condition, in the opinion of the investigator, preclude for compression therapy.

3. Subjects with paralysis of the study leg

4. Subjects who started or significantly changed treatment with mood altering substances (e.g. antidepressant drugs) within two weeks prior to enrollment.

5. Subjects with significant instable coagulopathy; subjects treated with anticoagulant therapeutics can be included.

6. Subjects who are participating in any prospective clinical study that can potentially interfere with this study.

8. Subjects with known allergies to other materials in the compression device.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

3M

INDUSTRY

Sponsor Role: collaborator

Solventum US LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Juenger, Prof. Dr. MD

Role: PRINCIPAL_INVESTIGATOR

Universitaetsklinikum Greifswald

Locations

Universitaetsklinikum Greifswald

Greifswald, , Germany

Countries

Germany

Other Identifiers

EU Study No-05-000007

Identifier Type: -

Identifier Source: org_study_id